Linked Life Data

17115221

Source:http://linkedlifedata.com/resource/pubmed/id/17115221

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2007-3-29
pubmed:abstractText
Cytokines are released during T cell activation, including the potentially anti-leukemic interferon-gamma (IFNgamma), but also the hematopoietic growth factor granulocyte-macrophage colony-stimulating factor (GM-CSF) that enhance proliferation and inhibit apoptosis of acute myelogenous leukemia (AML) cells. In the present study we investigated the release of IFNgamma and GM-CSF by circulating T cells in AML patients with chemotherapy-induced cytopenia. T cells were activated with anti-CD3 plus anti-CD28 in a whole-blood assay in the presence of their natural cytokine network. We examined 63 samples derived from 16 AML patients during 28 chemotherapy cycles. Activated T cells showed a broad cytokine release profile, but IFNgamma and GM-CSF levels showed a significant correlation and were generally higher than the other cytokine levels. Higher IFNgamma and GM-CSF responses were associated with a low CD4:CD8 ratio, older patient age and no ongoing chemotherapy indicating potential utility of T cell activation regimes for the older AML patient. The cytokine levels could be further increased by the novel protein kinase C agonist PEP005, which also induced significant production of IL2 and TNFalpha which could contribute to anti-tumor effects in AML patients. We conclude that remaining T cells after intensive AML therapy show a broad cytokine release profile including high and significantly correlated levels of potentially anti-leukemic IFNgamma and the AML growth factor GM-CSF. The final outcome of an AML-initiated T cell cytokine response will thus depend on the functional characteristics of the AML cells, in particular the relative expression of IFNgamma and GM-CSF receptors which differs between AML patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0340-7004
pubmed:author
pubmed:issnType
Print
pubmed:volume
56
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
913-25
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:17115221-Adult, pubmed-meshheading:17115221-Aged, pubmed-meshheading:17115221-Antineoplastic Agents, pubmed-meshheading:17115221-Cells, Cultured, pubmed-meshheading:17115221-Cytokines, pubmed-meshheading:17115221-Diterpenes, pubmed-meshheading:17115221-Esters, pubmed-meshheading:17115221-Female, pubmed-meshheading:17115221-Granulocyte-Macrophage Colony-Stimulating Factor, pubmed-meshheading:17115221-Humans, pubmed-meshheading:17115221-Interferon-gamma, pubmed-meshheading:17115221-Leukemia, Myeloid, Acute, pubmed-meshheading:17115221-Lymphocyte Activation, pubmed-meshheading:17115221-Lymphopenia, pubmed-meshheading:17115221-Male, pubmed-meshheading:17115221-Middle Aged, pubmed-meshheading:17115221-Protein Kinase C, pubmed-meshheading:17115221-T-Lymphocyte Subsets, pubmed-meshheading:17115221-T-Lymphocytes
pubmed:year
2007
pubmed:articleTitle
T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C agonist PEP005.
pubmed:affiliation
Section for Hematology, Institute of Medicine, The University of Bergen and Haukeland University Hospital, 5021 Bergen, Norway. elisabeth.ersvar@med.uib.no
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't